Hims & Hers Health (NYSE:HIMS) Releases Quarterly Earnings Results, Beats Estimates By $0.26 EPS

Hims & Hers Health (NYSE:HIMS) announced its quarterly earnings results on Monday. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26, Briefing.com reports. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period last year, the company posted ($0.04) EPS. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $0.74 during trading hours on Tuesday, hitting $21.50. 32,290,593 shares of the stock were exchanged, compared to its average volume of 8,437,679. The company’s fifty day simple moving average is $18.10 and its two-hundred day simple moving average is $18.19. Hims & Hers Health has a 1-year low of $6.23 and a 1-year high of $25.74. The company has a market cap of $4.62 billion, a PE ratio of 271.03 and a beta of 1.06.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of recent research reports. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. TD Cowen raised their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.71.

Insider Buying and Selling at Hims & Hers Health

In other news, Director Christiane Pendarvis sold 7,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the transaction, the director now owns 23,917 shares of the company’s stock, valued at approximately $362,342.55. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 269,739 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the sale, the chief financial officer now owns 145,763 shares of the company’s stock, valued at approximately $2,960,446.53. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christiane Pendarvis sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total transaction of $106,050.00. Following the completion of the transaction, the director now directly owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 650,659 shares of company stock valued at $11,712,198. 17.71% of the stock is currently owned by corporate insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.